Home | Business News | CBJ Newsmakers | Knight Therapeutics: Use of PROBUPHINE™ for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast Knight Therapeutics: Use of PROBUPHINE™ for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast RecommendedNorthland Power Announces 2023 Financial Guidance, Expands Canadian Development Portfolio and Establishes Its 2040 Net Zero TargetDescartes Sets Date to Announce Fiscal 2023 Fourth Quarter and Year-End Financial ResultsPowerTap Named as Industry Partner to ARCHES, California’s Public-Private Hydrogen Hub Consortium
